Polycystic ovary syndrome is one of the most common hormonal conditions in women of reproductive age, and most people who live with it describe years of delay before a name is put to their symptoms, followed by fragmented, symptom-by-symptom care. That gap is where a well-built telehealth pathway earns its place: not as a diagnostic shortcut, but as a structured way to manage the menstrual, dermatological and metabolic sides of PCOS once the diagnosis is confirmed or reasonably assumed.
Why PCOS is a genuine telehealth opportunity, and a limited one
PCOS is a long-term condition managed through repeat prescribing, cycle tracking and periodic review, which is exactly the pattern telehealth handles well elsewhere: hypertension, thyroid, cholesterol. Patients already juggle several strands of care (a combined pill for cycle control, metformin for insulin resistance, sometimes an anti-androgen for hirsutism or acne) and a single structured pathway can coordinate all three instead of leaving the patient to manage separate prescriptions from separate places.
The limit is diagnosis. PCOS is diagnosed clinically using the Rotterdam criteria, which needs two of three: irregular or absent ovulation, clinical or biochemical signs of excess androgen, and polycystic ovaries on pelvic ultrasound. A remote consultation can take a thorough history and note clinical signs, but it cannot perform an ultrasound, and most telehealth operators do not run in-house phlebotomy. Build the service around that constraint rather than around it.
The diagnosis problem: what a remote service can and can't confirm
Two workable models exist. The first treats patients who already have a documented PCOS diagnosis from a GP or gynaecologist, which sidesteps the diagnostic question entirely and lets the service focus on ongoing prescribing and review. The second accepts patients with a strong clinical picture (irregular cycles plus androgenic symptoms) who haven't completed formal workup, and signposts them to NHS or private routes for the bloods and ultrasound that would confirm it, while managing symptoms qualitatively described as "suspected PCOS" in the meantime.
What doesn't work is presenting a symptom questionnaire as a diagnostic tool. NICE guidance and the relevant Royal College guidance are clear that the Rotterdam criteria require clinical and, where relevant, imaging or biochemical confirmation, not just a self-reported symptom checklist. A telehealth service that blurs this line, even unintentionally through marketing copy, creates both a clinical safety problem and an ASA/CAP advertising risk: claims should never suggest the service itself diagnoses PCOS.
First-line prescribing: the combined pill, metformin and anti-androgens
For patients wanting cycle regulation and improvement in acne or hirsutism, a combined oral contraceptive is usually first-line, subject to the same contraindication screening (migraine with aura, VTE risk, smoking status, BMI) used in any online contraception pathway. Metformin is prescribed off-label for PCOS in the UK to improve insulin sensitivity and, in some patients, menstrual regularity; it isn't licensed for this indication, so consent documentation should record that explicitly, in the same way an off-label pathway would for any other condition.
For hirsutism or acne that doesn't respond to the combined pill alone, co-cyprindiol or spironolactone are commonly used anti-androgens, both requiring reliable contraception because of teratogenic risk and both needing a documented discussion of that risk before the first prescription. Prescriber discretion applies throughout, and none of this removes the need for a named prescriber who reviews the full medication list, not just the presenting symptom.
- Combined pill for cycle regulation, hirsutism and acne, subject to standard cardiovascular and VTE screening
- Metformin (off-label) for insulin resistance and, in some patients, cycle improvement
- Spironolactone or co-cyprindiol (off-label, anti-androgen) with mandatory contraception counselling
- Topical or oral acne treatment run alongside, not instead of, the hormonal picture
- Lifestyle and dietetic support offered as a genuine first-line option, not a token add-on
Treat a documented or strongly suspected PCOS diagnosis, not a symptom questionnaire, as the entry point to prescribing; the service's job is structured ongoing management, not diagnosis.
Weight, insulin resistance and where GLP-1 fits
Insulin resistance is central to many PCOS presentations, and weight management genuinely helps symptoms for patients who are living with excess weight. Several operators now want to fold a GLP-1 pathway into their PCOS offer, and there's a reasonable clinical case for it. The mistake is treating a PCOS diagnosis as a shortcut around standard weight-management eligibility.
PCOS patients seeking GLP-1 treatment should go through the same NICE-aligned access criteria (BMI thresholds, comorbidity assessment, structured lifestyle support) as any other patient on a GLP-1 weight-management pathway, not a PCOS-specific bypass. Where a patient meets both the PCOS criteria and the standard weight-management criteria, coordinating the two prescriptions under one clinical record, rather than two disconnected services, is where telehealth adds real value.
Red flags and the referral line
Amenorrhoea lasting several months needs attention beyond "irregular periods are normal in PCOS": prolonged unopposed oestrogen exposure carries a long-term endometrial risk that most guidance addresses with periodic withdrawal bleeds or endometrial assessment, and a telehealth service should have a clear protocol for when that conversation happens, not leave it to chance. Rapid-onset or severe virilisation (significant voice change, marked hair loss pattern, clitoromegaly) is a red flag for a different, rarer androgen-secreting cause and needs urgent specialist referral, not routine PCOS management.
Fertility concerns sit outside most telehealth PCOS pathways entirely. Patients trying to conceive need referral to a fertility specialist or their GP for ovulation-induction options; metformin and spironolactone both carry specific guidance around pregnancy planning, and a service that keeps prescribing an anti-androgen to a patient who mentions she's trying to conceive has a documentation and safety failure, not just a clinical one.
The patients who fall through the cracks in PCOS care aren't usually undertreated on any one medication. They're on three separate ones that nobody is looking at together.
Building the review cadence and documentation
Each patient record should state clearly whether PCOS is confirmed (with the basis: prior ultrasound, prior bloods, specialist letter) or clinically suspected pending workup, because that status changes what the service can safely claim and prescribe. Review intervals should cover weight and blood pressure trends, contraindication changes, and a periodic check on menstrual pattern, with metformin and anti-androgen use flagged for consent renewal if the picture changes.
PCOS is also associated, in the wider literature, with higher rates of anxiety and low mood, so a brief mental health check within the review cadence, not a full assessment, is worth building in and documenting either way. None of this needs to be elaborate: a short structured template that a clinical SOP defines once and every prescriber follows consistently does more for patient safety than a longer but inconsistent note.
How PExpo supports a PCOS launch
PExpo's dispensing and prescribing infrastructure sits underneath the clinical model rather than replacing it: a superintendent pharmacist oversees the dispensing pipeline, prescriptions route through compliant electronic channels, and the consent and off-label documentation your clinical team builds attaches to the record rather than living in a separate system. For a condition like PCOS, where a single patient can be on a contraceptive, metformin and an anti-androgen at once, that single coordinated record is the difference between a joined-up service and three prescriptions that happen to share a logo.
Brands building a women's-health vertical already have most of the operational pieces PCOS needs: contraceptive prescribing pathways, consent workflows for off-label use, and a dispensing partner used to reviewing repeat prescriptions rather than one-off orders. PCOS is often less a new build than an extension of what's already there.
PCOS rewards patience more than most telehealth verticals: the diagnostic boundary has to be respected, the medication list has to be coordinated rather than siloed, and the referral lines for fertility and endometrial risk need to be built in from day one, not bolted on after an incident. Done properly, it sits naturally alongside an existing contraception or weight-management pathway rather than requiring a separate service. Talk to PExpo's white-label team about what the dispensing and compliance layer looks like for a PCOS launch.
Frequently asked questions
Can a telehealth service diagnose PCOS?
Not reliably on its own. Formal diagnosis uses the Rotterdam criteria, which typically needs a pelvic ultrasound and, often, blood tests alongside the clinical picture. Most telehealth services manage patients who already have a diagnosis, or signpost suspected cases to an NHS or private route for that workup, rather than diagnosing from a symptom questionnaire alone.
Is metformin licensed for PCOS in the UK?
No. Metformin is used off-label for PCOS to help with insulin resistance and, in some patients, cycle regularity. Prescribers should document that the use is off-label and record the patient's informed consent, the same approach used for other off-label prescribing in UK telehealth.
Can women with PCOS access GLP-1 weight-loss medication through telehealth?
Yes, but through the same NICE-aligned eligibility route as any other patient, covering BMI thresholds, comorbidities and structured lifestyle support, rather than a PCOS-specific shortcut. Where a patient qualifies for both PCOS management and a weight-management pathway, coordinating them under one clinical record is best practice.
